Panoptes Pharma GmbH logo

Panoptes Pharma GmbH

Panoptes Pharma is a clinical stage biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. Panoptes’ development program focuses on a new treatment for orphan autoimmune uveitis, a disease which is one of the major causes of blindness. For this indication, PP-001 is developed as long-acting intravitreal injectable. Further indications in Panoptes’ focus are dry eye disease and adenoviral conjunctivitis to be treated with eye drops.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.panoptes-pharma.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Reisnerstra_e 34/1, 1030
Vienna
Austria
Email
Contact Number
+43 1 8905697

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/panoptes-pharma-gmbh” connections=”true” suffix=””]